MEDI0382, a GLP-1 and Glucagon Receptor Dual Agonist, in Obese or Overweight Patients With Type 2 Diabetes: A Randomised, Controlled, Double-Blind, Ascending Dose and Phase 2a Study
Marketed By: Guru Kirpa Enterprises A-26, Vishal Enclave, Rajuri Garden, New Delhi-110027, OR Shri Balaji Overseas 731/1, Division 3, Phirni Road , Mundka, North West Delhi, India -110041, OR Shri Balaji Overseas KH
When lifestyle confounders change, note them before attributing outcomes to any peptide narrative
Research suggests these applications may give insights into preserving muscle function across various challenge conditions
As governments allocate more resources to combat obesity, innovative treatment options will likely gain traction